Barclays’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-116,113
| Closed | -$6M | – | 5599 |
|
|
2022
Q3 | $6M | Sell |
116,113
-430,999
| -79% | -$17.8M | 0.01% | 1060 |
|
|
2022
Q2 | $13.6M | Buy |
547,112
+505,000
| +1,199% | +$11.1M | 0.01% | 880 |
|
|
2022
Q1 | $1.06M | Sell |
42,112
-109,104
| -72% | -$3.07M | ﹤0.01% | 2355 |
|
|
2021
Q4 | $5.51M | Buy |
151,216
+22,867
| +18% | +$803K | ﹤0.01% | 1635 |
|
|
2021
Q3 | $2.19M | Buy |
128,349
+47,061
| +58% | +$733K | ﹤0.01% | 2265 |
|
|
2021
Q2 | $1.09M | Sell |
81,288
-14,165
| -15% | -$349K | ﹤0.01% | 2610 |
|
|
2021
Q1 | $4.89M | Buy |
95,453
+78,280
| +456% | +$4.71M | ﹤0.01% | 1538 |
|
|
2020
Q4 | $1.06M | Sell |
17,173
-66,454
| -79% | -$3.8M | ﹤0.01% | 2715 |
|
|
2020
Q3 | $4.58M | Buy |
83,627
+51,152
| +158% | +$2.75M | ﹤0.01% | 1452 |
|
|
2020
Q2 | $1.87M | Buy |
32,475
+18,874
| +139% | +$1.03M | ﹤0.01% | 2186 |
|
|
2020
Q1 | $548K | Sell |
13,601
-29,217
| -68% | -$1.24M | ﹤0.01% | 3507 |
|
|
2019
Q4 | $1.69M | Sell |
42,818
-18,365
| -30% | -$322K | ﹤0.01% | 3177 |
|
|
2019
Q3 | $414K | Sell |
61,183
-21,257
| -26% | -$160K | ﹤0.01% | 4396 |
|
|
2019
Q2 | $767K | Buy |
82,440
+69,326
| +529% | +$803K | ﹤0.01% | 3957 |
|
|
2019
Q1 | $182K | Buy |
13,114
+7,248
| +124% | +$82.9K | ﹤0.01% | 4893 |
|
|
2018
Q4 | $63K | Sell |
5,866
-9,438
| -62% | -$99.5K | ﹤0.01% | 5354 |
|
|
2018
Q3 | $194K | Buy |
15,304
+6,815
| +80% | +$82.1K | ﹤0.01% | 5030 |
|
|
2018
Q2 | $112K | Sell |
8,489
-4,577
| -35% | -$54.7K | ﹤0.01% | 5171 |
|
|
2018
Q1 | $178K | Buy |
13,066
+8,621
| +194% | +$88.9K | ﹤0.01% | 4934 |
|
|
2017
Q4 | $26K | Buy |
4,445
+2,680
| +152% | +$18.4K | ﹤0.01% | 6162 |
|
|
2017
Q3 | $13K | Sell |
1,765
-1,771
| -50% | -$14.7K | ﹤0.01% | 6021 |
|
|
2017
Q2 | $33K | Sell |
3,536
-299
| -8% | -$2.19K | ﹤0.01% | 5563 |
|
|
2017
Q1 | $27K | Buy |
3,835
+1,828
| +91% | +$13.2K | ﹤0.01% | 5678 |
|
|
2016
Q4 | $15K | Buy |
2,007
+1,827
| +1,015% | +$13.2K | ﹤0.01% | 5756 |
|
|
2016
Q3 | $1K | Sell |
180
-6,095
| -97% | -$28.8K | ﹤0.01% | 6485 |
|
|
2016
Q2 | $28K | Buy |
6,275
+6,039
| +2,559% | +$22.7K | ﹤0.01% | 5136 |
|
|
2016
Q1 | $0 | Sell |
236
-3,601
| -94% | -$13.1K | ﹤0.01% | 6534 |
|
|
2015
Q4 | $31K | Sell |
3,837
-8,139
| -68% | -$57.6K | ﹤0.01% | 5029 |
|
|
2015
Q3 | $72K | Buy |
11,976
+11,423
| +2,066% | +$82.6K | ﹤0.01% | 4816 |
|
|
2015
Q2 | $4K | Sell |
553
-467
| -46% | -$3.71K | ﹤0.01% | 6599 |
|
|
2015
Q1 | $6K | Sell |
1,020
-118,390
| -99% | -$925K | ﹤0.01% | 6523 |
|
|
2014
Q4 | $717K | Buy |
119,410
+95,874
| +407% | +$507K | ﹤0.01% | 3502 |
|
|
2014
Q3 | $94K | Buy |
23,536
+2,074
| +10% | +$11K | ﹤0.01% | 5381 |
|
|
2014
Q2 | $108K | Sell |
21,462
-6,423
| -23% | -$36K | ﹤0.01% | 5353 |
|
|
2014
Q1 | $168K | Buy |
27,885
+11,839
| +74% | +$82.3K | ﹤0.01% | 4954 |
|
|
2013
Q4 | $79K | Buy |
16,046
+10,020
| +166% | +$51.7K | ﹤0.01% | 5847 |
|
|
2013
Q3 | $31K | Buy |
6,026
+4,748
| +372% | +$51.3K | ﹤0.01% | 6325 |
|
|
2013
Q2 | $18K | Buy |
+1,278
| New | +$16.6K | ﹤0.01% | 6889 |
|
Other funds holding CCXI
Barclays's CCXI Position: Q4 2022 in Review
Barclays sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 116,113 shares — an estimated $6M sold.
Barclays first reported a position in CCXI in Q2 2013 and held it in 38 quarters. The position peaked at $13.6M in Q2 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Barclays reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Barclays sold 116,113 ChemoCentryx, Inc. shares in Q4 2022, an estimated $6M.
- Barclays first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 38 quarters.
- Barclays's ChemoCentryx, Inc. position peaked at $13.6M in Q2 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.